Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2022 Mar 2

PMID 35234860

Authors

Martin Hoenigl

Daniela Abramovitz

Ricardo E Flores Ortega

Natasha K Martin

Nancy Reau

Affiliations

Soon will be listed here.

Abstract

Background: Recent reports indicated declines in hepatitis C virus (HCV) testing during the first half of 2020 in the United States due to coronavirus disease 2019 (COVID-19), but the longer-term impact on HCV testing and treatment is unclear.

Methods: We obtained monthly state-level volumes of HCV antibody, RNA and genotype testing, and HCV treatment initiation, stratified by age and gender, spanning January 2019 until December 2020 from 2 large national laboratories. We performed segmented regression analysis for each state from a mixed-effects Poisson regression model with month as the main fixed predictor and state as a random intercept.

Results: During the pre-COVID-19 period (January 2019-March 2020), monthly HCV antibody and genotype tests decreased slightly whereas RNA tests and treatment initiations remained stable. Between March and April 2020, there were declines in the number of HCV antibody tests (37% reduction, P < .001), RNA tests (37.5% reduction, P < .001), genotype tests (24% reduction, P = .023), and HCV treatment initiations (31%, P < .001). Starting April 2020 through the end of 2020, there were significant increases in month-to-month HCV antibody (P < .001), RNA (P = .035), and genotype tests (P = .047), but only antibody testing rebounded to pre-COVID-19 levels. HCV treatment initiations remained low after April 2020 throughout the remainder of the year.

Conclusions: HCV testing and treatment dropped by >30% during April 2020 at the start of the COVID-19 pandemic, but although HCV testing increased again later in 2020, HCV treatment rates did not recover. Efforts should be made to link HCV-positive patients to treatment and revitalize HCV treatment engagement by healthcare providers.

Citing Articles

Road to Hepatitis C Elimination in Israel: Improvements in Linkage to Care (2009-2020).

Basson A, Weil C, Marx S, Dylla D, Collins M, Hadadi S Adv Ther. 2025; 42(3):1522-1536.

PMID: 39912989 PMC: 11868148. DOI: 10.1007/s12325-024-03102-6.

How far are we? Assessing progress in hepatitis C response towards the WHO 2030 elimination goals by the civil society monitoring in 25 European countries, period 2020 to 2023.

Maticic M, Cernosa J, Loboda C, Tamse J, Rigoni R, Duffell E Harm Reduct J. 2024; 21(1):203.

PMID: 39563360 PMC: 11577836. DOI: 10.1186/s12954-024-01115-6.

Modeling the impact of the COVID-19 pandemic on achieving HCV elimination amongst young and unstably housed people who inject drugs in San Francisco.

Fraser H, Stone J, Facente S, Artenie A, Patel S, Wilson E Int J Drug Policy. 2024; 131:104452.

PMID: 38910096 PMC: 7617003. DOI: 10.1016/j.drugpo.2024.104452.

Impact of Public Policy and COVID-19 Pandemic on Hepatitis C Testing and Treatment in France, 2014-2021.

Brouard C, Schwager M, Expert A, Drewniak N, Laporal S, de Lagasnerie G Viruses. 2024; 16(5).

PMID: 38793673 PMC: 11125660. DOI: 10.3390/v16050792.

Impact of the COVID-19 Pandemic on Hepatitis C Treatment Initiation in British Columbia, Canada: An Interrupted Time Series Study.

Morrow R, Binka M, Li J, Irvine M, Bartlett S, Wong S Viruses. 2024; 16(5).

PMID: 38793537 PMC: 11125629. DOI: 10.3390/v16050655.

References

Dubey M, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S . COVID-19 and addiction. Diabetes Metab Syndr. 2020; 14(5):817-823. PMC: 7282772. DOI: 10.1016/j.dsx.2020.06.008. View

Rick F, Odoke W, van den Hombergh J, Benzaken A, Avelino-Silva V . Impact of coronavirus disease (COVID-19) on HIV testing and care provision across four continents. HIV Med. 2021; 23(2):169-177. PMC: 8653012. DOI: 10.1111/hiv.13180. View

Wagner A, Soumerai S, Zhang F, Ross-Degnan D . Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27(4):299-309. DOI: 10.1046/j.1365-2710.2002.00430.x. View

Pley C, McNaughton A, Matthews P, Lourenco J . The global impact of the COVID-19 pandemic on the prevention, diagnosis and treatment of hepatitis B virus (HBV) infection. BMJ Glob Health. 2021; 6(1). PMC: 7786543. DOI: 10.1136/bmjgh-2020-004275. View

Sperring H, Ruiz-Mercado G, Schechter-Perkins E . Impact of the 2020 COVID-19 Pandemic on Ambulatory Hepatitis C Testing. J Prim Care Community Health. 2020; 11:2150132720969554. PMC: 7686585. DOI: 10.1177/2150132720969554. View

Hensley K, Jordans C, van Kampen J, Mollema F, Gisolf E, El Moussaoui R . Significant Impact of Coronavirus Disease 2019 (COVID-19) on Human Immunodeficiency Virus (HIV) Care in Hospitals Affecting the First Pillar of the HIV Care Continuum. Clin Infect Dis. 2021; 74(3):521-524. PMC: 8244584. DOI: 10.1093/cid/ciab445. View

Ryerson A, Schillie S, Barker L, Kupronis B, Wester C . Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018. MMWR Morb Mortal Wkly Rep. 2020; 69(14):399-404. PMC: 7147907. DOI: 10.15585/mmwr.mm6914a2. View

Chaillon A, Mehta S, Hoenigl M, Solomon S, Vickerman P, Hickman M . Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One. 2019; 14(6):e0217964. PMC: 6553784. DOI: 10.1371/journal.pone.0217964. View

Hoenigl M, Mathur K, Blumenthal J, Brennan J, Zuazo M, McCauley M . Universal HIV and Birth Cohort HCV Screening in San Diego Emergency Departments. Sci Rep. 2019; 9(1):14479. PMC: 6785532. DOI: 10.1038/s41598-019-51128-6. View

10.

Balakrishnan M, Kanwal F . The HCV Treatment Cascade: Race Is a Factor to Consider. J Gen Intern Med. 2019; 34(10):1949-1951. PMC: 6816660. DOI: 10.1007/s11606-019-04962-3. View

11.

Kaufman H, Bull-Otterson L, Meyer 3rd W, Huang X, Doshani M, Thompson W . Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic. Am J Prev Med. 2021; 61(3):369-376. PMC: 8107198. DOI: 10.1016/j.amepre.2021.03.011. View

12.

Nili M, Luo L, Feng X, Chang J, Tan X . Disparities in hepatitis C virus infection screening among Baby Boomers in the United States. Am J Infect Control. 2018; 46(12):1341-1347. DOI: 10.1016/j.ajic.2018.06.008. View

13.

Martin N, Thornton A, Hickman M, Sabin C, Nelson M, Cooke G . Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clin Infect Dis. 2016; 62(9):1072-1080. PMC: 4826456. DOI: 10.1093/cid/ciw075. View

14.

Hall E, Rosenberg E, Sullivan P . Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010. BMC Infect Dis. 2018; 18(1):224. PMC: 5956841. DOI: 10.1186/s12879-018-3133-6. View

15.

Mathur K, Blumenthal J, Horton L, Wagner G, Martin T, Lo M . HIV screening in emergency departments: Linkage works but what about retention?. Acad Emerg Med. 2020; 28(8):913-917. PMC: 8196073. DOI: 10.1111/acem.14194. View

16.

Durbin J, Watson G . Testing for serial correlation in least squares regression. II. Biometrika. 1951; 38(1-2):159-78. View

17.

Ford J, Chechi T, Toosi K, Mahmood B, Meehleis D, Otmar M . Universal Screening for Hepatitis C Virus in the ED Using a Best Practice Advisory. West J Emerg Med. 2021; 22(3):719-725. PMC: 8203013. DOI: 10.5811/westjem.2021.1.49667. View

18.

Stanford K, McNulty M, Schmitt J, Eller D, Ridgway J, Beavis K . Incorporating HIV Screening With COVID-19 Testing in an Urban Emergency Department During the Pandemic. JAMA Intern Med. 2021; 181(7):1001-1003. PMC: 8042563. DOI: 10.1001/jamainternmed.2021.0839. View

19.

Moore K, Gauri A, Koru-Sengul T . Prevalence and sociodemographic disparities of Hepatitis C in Baby Boomers and the US adult population. J Infect Public Health. 2018; 12(1):32-36. DOI: 10.1016/j.jiph.2018.08.003. View

20.

Edlin B, Eckhardt B, Shu M, Holmberg S, Swan T . Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015; 62(5):1353-63. PMC: 4751870. DOI: 10.1002/hep.27978. View